CONCORDBIO — Concord Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹162.50bn
- IN₹159.35bn
- IN₹10.17bn
Annual cashflow statement for Concord Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 2,136 | 3,127 | 2,375 | 3,220 | 4,126 |
| Depreciation | |||||
| Non-Cash Items | -92 | -94.9 | 27.4 | -51.9 | -162 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -708 | -1,639 | -828 | -1,249 | -1,845 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 1,548 | 1,668 | 2,075 | 2,460 | 2,655 |
| Capital Expenditures | -1,555 | -2,042 | -1,555 | -1,451 | -857 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 427 | 89.7 | 437 | -129 | -689 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1,128 | -1,952 | -1,118 | -1,580 | -1,546 |
| Financing Cash Flow Items | -808 | -57.1 | -727 | -48.8 | -12.6 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -434 | 311 | -1,002 | -852 | -992 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -13.5 | 27.4 | -44.8 | 28.3 | 116 |